Israel Englander Checkpoint Therapeutics, Inc. Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.02 - $10.6 $293,339 - $3.05 Million	-287,588 Reduced 34.26%	551,794 $574,000
Q2 2022 Aug 15, 2022	SELL	$0.97 - $1.77 $285,612 - $521,169	-294,446 Reduced 25.97%	839,382 $865,000
Q1 2022 May 16, 2022	BUY	$1.53 - $3.25 $498,435 - $1.06 Million	325,775 Added 40.32%	1,133,828 $2.01 Million
Q4 2021 Feb 14, 2022	SELL	$2.68 - $4.46 $80,740 - $134,366	-30,127 Reduced 3.59%	808,053 $2.51 Million
Q3 2021 Nov 15, 2021	SELL	$2.5 - $3.53 $468,130 - $660,999	-187,252 Reduced 18.26%	838,180 $2.77 Million
Q2 2021 Aug 16, 2021	BUY	$2.36 - $3.2 $2.12 Million - $2.88 Million	899,834 Added 716.44%	1,025,432 $3.03 Million
Q1 2021 May 17, 2021	SELL	$2.6 - $4.16 $668,428 - $1.07 Million	-257,088 Reduced 67.18%	125,598 $394,000
Q4 2020 Feb 16, 2021	BUY	$2.19 - $2.96 $599,582 - $810,394	273,782 Added 251.4%	382,686 $1.01 Million
Q3 2020 Nov 16, 2020	BUY	$1.62 - $4.24 $20,710 - $54,204	12,784 Added 13.3%	108,904 $292,000
Q2 2020 Aug 14, 2020	BUY	$1.19 - $2.27 $61,970 - $118,212	52,076 Added 118.24%	96,120 $190,000
Q1 2020 May 14, 2020	SELL	$1.11 - $2.43 $44,676 - $97,805	-40,249 Reduced 47.75%	44,044 $67,000
Q4 2019 Feb 14, 2020	BUY	$1.18 - $2.39 $99,465 - $201,460	84,293 New	84,293 $145,000
Q3 2019 Nov 14, 2019	SELL	$2.15 - $3.36 $87,947 - $137,444	-40,906 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$2.75 - $5.0 $112,491 - $204,530	40,906 New	40,906 $124,000
Q2 2018 Aug 14, 2018	SELL	$2.45 - $4.39 $184,705 - $330,962	-75,390 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$3.24 - $5.6 $244,263 - $422,184	75,390 New	75,390 $331,000

Others Institutions Holding CKPT

# of Institutions

Shares Held

1.91M

Call Options Held

Put Options Held

View Full List

About Checkpoint Therapeutics, Inc.

Ticker CKPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,497,000
Market Cap $351M
Description
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...

More about CKPT

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account